264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021

Industry participants; Workshop Participants

doi:10.1016/j.nmd.2022.06.005

264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021

Industry participants, Workshop Participants

Research output: Contribution to journal › Journal article › Research › peer-review

7 Citations (Scopus)

7 Downloads (Pure)

Original language	English
Journal	Neuromuscular Disorders
Volume	32
Issue number	8
Pages (from-to)	697-705
Number of pages	9
ISSN	0960-8966
DOIs	https://doi.org/10.1016/j.nmd.2022.06.005
Publication status	Published - 2022

Access to Document

10.1016/j.nmd.2022.06.005

FulltextAccepted author manuscript, 884 KB
FulltextFinal published version, 452 KB

Cite this

@article{25e7cd6e1c1f495f9bd3ac3007bc0808,

title = "264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021",

author = "Detering, {Nora Tula} and Alberto Zambon and Niko Hensel and Rashmi Kothary and Kathryn Swoboda and Gillingwater, {Thomas H.} and Giovanni Baranello and John Vissing and {Industry participants} and {Workshop Participants}",

note = "Funding Information: GB has received speaker and consulting fees from Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche and has worked as principal investigator of SMA studies sponsored by Novartis Gene Therapies, Inc., and Roche. The other organizers do not have conflicts to declare for this specific workshop.We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Fran{\c c}aise contre les Myopathies (France), Deutsche Gesellschaft f{\"u}r Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung f{\"u}r die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and {\"O}sterreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185. Funding Information: We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Fran{\c c}aise contre les Myopathies (France), Deutsche Gesellschaft f{\"u}r Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung f{\"u}r die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and {\"O}sterreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185 .",

year = "2022",

doi = "10.1016/j.nmd.2022.06.005",

language = "English",

volume = "32",

pages = "697--705",

journal = "Journal of Neuromuscular Diseases",

issn = "0960-8966",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - 264th ENMC International Workshop

T2 - Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021

AU - Detering, Nora Tula

AU - Zambon, Alberto

AU - Hensel, Niko

AU - Kothary, Rashmi

AU - Swoboda, Kathryn

AU - Gillingwater, Thomas H.

AU - Baranello, Giovanni

AU - Vissing, John

AU - Industry participants

AU - Workshop Participants

N1 - Funding Information: GB has received speaker and consulting fees from Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche and has worked as principal investigator of SMA studies sponsored by Novartis Gene Therapies, Inc., and Roche. The other organizers do not have conflicts to declare for this specific workshop.We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Française contre les Myopathies (France), Deutsche Gesellschaft für Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung für die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and Österreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185. Funding Information: We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Française contre les Myopathies (France), Deutsche Gesellschaft für Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung für die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and Österreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185 .

PY - 2022

Y1 - 2022

U2 - 10.1016/j.nmd.2022.06.005

DO - 10.1016/j.nmd.2022.06.005

M3 - Journal article

C2 - 35794048

AN - SCOPUS:85133386413

VL - 32

SP - 697

EP - 705

JO - Journal of Neuromuscular Diseases

JF - Journal of Neuromuscular Diseases

SN - 0960-8966

IS - 8

ER -